High-throughput oncogene mutation profiling in human cancerRoman K. Thomas, Meenhard Herlyn, Jeffrey C. Lee et al.|Nature Genetics|2007Cited by 996
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancerMartin L. Sos, Roman K. Thomas, Stefanie Fischer et al.|Proceedings of the National Academy of Sciences|2009Cited by 255
The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGISalah‐Eddin Al‐Batran, Stefan Paul Moenig, Thorsten Oliver Goetze et al.|BMC Cancer|2017Cited by 226
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancerJohanna C. Bendell, Michael Thomas, Helge Bischoff et al.|Investigational New Drugs|2019Cited by 30
Combined score of Y chromosome loss and T-cell infiltration improves UICC based stratification of esophageal adenocarcinomaVerena Maria Raters, Thomas Zander|Frontiers in Oncology|2023Cited by 7